[1]刘雪频,黄仁发,高 玉,等.M 型磷脂酶 A2 受体与特发性膜性肾病及中医证型的研究[J].大众科技,2019,21(12):47-49.
　Study of PLA2R and Idiopathic Membranous Nephropathy with TCM Syndrome[J].Popular Science & Technology,2019,21(12):47-49.
点击复制

M 型磷脂酶 A2 受体与特发性膜性肾病及中医证型的研究()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
21
期数:
2019年12
页码:
47-49
栏目:
医药与卫生
出版日期:
2019-12-20

文章信息/Info

Title:
Study of PLA2R and Idiopathic Membranous Nephropathy with TCM Syndrome
作者:
刘雪频1;  黄仁发 2 ; 高 玉 3;  李美丹 1 ; 姚 兰 1 ; 王 玮 1
（1.广西中医药大学，广西 南宁 530299；2.广州中医药大学深圳医院（福田），广东 深圳 518034；3.河南省驻马店市中医院，河南 驻马店 463000）
关键词:
膜性肾病 ; M 型磷脂酶 A2 受体; 中医证型
Keywords:
membranous nephropathy;  PLA2R;  TCM syndrome
文献标志码:
A
摘要:
目的：检测肾组织中磷脂酶 A2 受体（M-type phospholipase A2 receptor，PLA2R）的表达，探究肾组织中 PLA2R与特发性膜性肾病及中医证型的联系。方法：回顾性分析 2016 年 4 月至 2019 年 6 月广西中医药大学附属瑞康医院经肾活检证实的 70 例肾病综合征（nephrotic syndrome，NS）患者作为研究对象，其中包括 30 例特发性膜性肾病、1 例乙型肝炎病毒相关性膜性肾病、2 例 V 型狼疮肾炎、6 例 Ig A 肾病、6 例微小病变性肾病、4 例系膜增生性肾小球肾炎和 1 例局灶节段性肾小球硬化及 20 例非膜性肾小球疾病。结果：（1）IMN 组、SMN 组、对照组 PLA2R 在肾脏组织表达的阳性率分别为 22/30（73.33%）、6/20（30%）、3/20（15%），三组间肾组织 PLA2R 的表达有显著统计学差异（P＜0.05）；（2）三组患者实验室指标相比较，血肌酐、血清白蛋白、尿β2 微球蛋白、24 h 尿蛋白定量、总胆固醇均无统计学差异（P＞0.05）；（3）中医证型与肾组织 PLA2R 的表达之间差异无统计学意义（P＞0.05）。结论：（1）肾组织 PLA2R 的表达可用于 MN，可用于 IMN 和 SMN 的鉴别诊断；（2）中医证型与相关指标有一定的相关性，与肾组织 PLA2R 的表达不存在相关性。
Abstract:
Objective: To detect the expression of M-type phospholipase A2 receptor (PLA2R) in renal tissue and explore therelationship between PLA2R and idiopathic membranous nephropathy and TCM syndrome types Methods: From April 2016 to June2019, 70 cases of nephrotic syndrome (NS) confirmed by renal biopsy in Ruikang Hospital Affiliated to Guangxi University oftraditional Chinese medicine were analyzed retrospectively, including 30 cases of idiopathic membranous nephropathy, 1 case ofhepatitis B-related membranous nephropathy, 2 cases of lupus nephritis, 6 cases of IgA nephropathy, 6 cases of microdegenerativenephropathy, 4 cases of mesangial hyperplasia One case of focal segmental glomerulonephritis and 20 cases of non membranousglomerulonephritis. Results: 1.The positive rate of PLA2R in IMN group,SMN group and control group was 22/30(73.33%)、6/20(30%)、3/20(15%), respectively. There were significant differences in the expression of PLA2R in renal tissues among the three groups (P＜0.05); 2. There was no significant difference in serum creatinine, serum albumin, urine β2 microglobulin, 24 hour urine protein and totalchoestetol among the three groups (P＞0.05); 3. There was no significant difference in the expression of PLA2R between TCMsyndromes type and renal tissue ( P＞0. 05). Conclusion：1. The expression of PLA2R in renal tissue can be used for MN and for thedifferential diagnosis of IMN and SMN. 2. There is a certain correlation between TCM syndrome and related indexes, but no correlationbetween TCM syndromes and the expression of PLA2R in renal tissue.

参考文献/References:

[1] Glassock R J. Pathogenesis of membranous nephropathy: anew paradigm in evolution[J]. Contributions to nephrology,2013, 181(181): 131-142.[2] Liu Y, Li X, Ma C, et al. Serum anti-PLA2R antibody as adiagnostic biomarker of idiopathic membranousnephropathy: the optimal cut-off value for Chinesepatients[J]. Clinica chimica act, 2018(476): 9-14.[3] Li J, Cui Z, Long J, et al. Primary glomerular nephropathyamong hospitalized patients in a national database inChina[J]. Nephrology Dialysis Transplantation, 2018,33(12): 2173-2181.[4] 韩秋霞，朱晗玉. 血清 PLA2R 抗体及 THSD7A 抗体对特发性膜性肾病的临床意义[J]. 中华检验医学杂志，2017，40(8): 564-568.[5] Beck L H , Bonegio R G B , Lambeau G, et al. M-TypePhospholipase A 2 Receptor as Target Antigen in IdiopathicMembranous Nephropathy[J]. New England Journal ofMedicine, 2009, 361(1): 11-21.[6] 王海燕. 肾脏病学(第 3 版)[M]. 北京: 人民卫生出版社，2008: 924.[7] 邹万忠. 肾活检病理学(第 2 版)[M]. 北京: 北京大学医学出版社，2009: 71-75.[8] 郑筱萸. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社，2002: 156-162.[9] Xu X, Wang G, Chen N, et al. Long-term exposure to airpollution and increased risk of membranous nephropathy inChina[J]. Journal of the American Society of Nephrology,2016, 27(12): 3739-3746 .[10] Qin W, Beck L H, Zeng C, et al. Anti-Phospholipase A2Receptor Antibody in Membranous Nephropathy[J]. Journalof the American Society of Nephrology, 2011, 22(6):1137-1143.[11] Ardalan M, Ghafari A, Hamzavi F, et al. Anti-phospholipaseA2 receptor antibody in idiopathic membranousnephropathy: A report from Iranian population[J].J Nephropathol, 2013，18(6): 241-248.[12] Akiyama S, Akiyama M, Imai E, et al. Prevalence ofanti-phospholipase A2 receptor antibodies in Japanesepatients with membranous nephropathy[J]. Clinical andExperimental Nephrology, 2015, 19(4): 653-660.[13] Wen J, Xie K, Zhang M, et al. HLA-DR, and not PLA2R, isexpressed on the podocytes in kidney allografts in de novomembranous nephropathy[J]. Medicine, 2016, 95(37) :e4809．[14] Ge Y C, Jin B, Zeng C H, et al. PLA2R antibodies andPLA2R glomerular deposits in psoriasis patients withmembranous nephropathy[J]. BMC Nephrology, 2016,17(1): 185．[15] 李园园，何灵芝，陈红波，等. 50 例膜性肾病临床表现、病理特点与中医证型的相关性分析[J]. 安徽中医药大学学报，2012，31(6): 32-34.[16] Hara S, Goto S, Kamiura N, et al. Reappraisal of PLA2R1 inmembranous nephropathy: immunostaining methodinfluence and association with IgG4-dominant phenotype[J]. Virchows Arch, 2015, 467(1): 87-94．[17] Jung O Y , Hee Y S, Ki K D, et al. Autoantibodies againstPhospholipase A2 Receptor in Korean Patients withMembranous Nephropathy[J]. PLOS ONE, 2013, 8(4):e62151.[18] 祝爽爽，周树录，周朝敏，等. 成人特发性膜性肾病肾组织 M 型磷脂酶 A2 受体 1 抗原的检测[J]. 南方医科大学学报，2015(4): 70-73.

备注/Memo

备注/Memo:
【收稿日期】2019-10-07【基金项目】国家自然科学基金资助项目（No.81460682，No. 81760805）；广西中医药大学 2019 年研究生教育创新计划项目（No. YCSY20190074）。【作者简介】刘雪频（1994－），女，湖南娄底人，广西中医药大学在读硕士研究生，研究方向为急慢性肾衰竭的中西结合防治。【通信作者】黄仁发，男，广州中医药大学深圳医院(福田)主任医师，从事急慢性肾衰竭的中西医治疗。
更新日期/Last Update: 2020-03-10